Advertisement
Screener

NEXENTIS TECHNOLOGIES INC. (NXTS) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

NEXENTIS TECHNOLOGIES INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest

NEXENTIS TECHNOLOGIES INC. (NXTS) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $1.78 million as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-13

  • 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1.78M.
  • 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $12.86M.
  • 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $15.73M.
  • 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $8.68M.
Period endStockholders' Equity, Including Portion Attributable to Noncontrolling InterestStockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed
2026-06-30$1.78M
10-Q · filed 2026-08-13
2026-03-31$12.86M
10-Q · filed 2026-08-13
2025-12-31$15.73M
10-Q · filed 2026-08-13
2025-09-30$8.68M
10-Q · filed 2025-11-13
2025-06-30$5.55M
10-Q · filed 2026-08-13
2025-03-31$3.70M
10-Q · filed 2026-08-13
2024-12-31$4.57M
10-Q · filed 2026-08-13
2024-09-30$5.30M
10-Q · filed 2025-11-13
$5.30M
10-Q · filed 2024-11-14
2024-06-30$5.89M
10-Q · filed 2025-11-13
$5.89M
10-Q · filed 2024-08-14
2024-03-31$5.70M
10-Q · filed 2025-11-13
$5.70M
10-Q · filed 2024-05-15
2023-12-31$6.46M
10-K · filed 2026-03-31
$6.46M
10-K · filed 2024-04-01
2023-09-30$4.62M
10-Q · filed 2024-11-14
2023-06-30$5.56M
10-Q · filed 2024-11-14
2023-03-31$4.77M
10-Q · filed 2024-11-14
2022-12-31$5.74M
10-K · filed 2025-03-31
$5.74M
10-K · filed 2023-03-27
2022-09-30$7.02M
10-Q · filed 2023-11-14
2022-06-30$4.39M
10-Q · filed 2023-11-14
2022-03-31$5.36M
10-Q · filed 2023-11-14
2021-12-31$6.41M
10-K · filed 2024-04-01
2021-09-30$7.83M
10-Q · filed 2022-11-14
2021-06-30$8.92M
10-Q · filed 2022-11-14
2021-03-31-$875.25K
10-Q · filed 2022-11-14
2020-12-31-$465.45K
10-K · filed 2023-03-27
2020-09-30-$370.93K
10-Q · filed 2021-11-15
2020-06-30-$412.07K
10-Q · filed 2021-11-15
2020-03-31-$701.08K
10-Q · filed 2021-11-15
2019-12-31-$402.12K
10-K · filed 2022-03-31
2019-09-30-$125.26K
10-Q · filed 2020-11-12
2019-06-30$210.96K
10-Q · filed 2020-08-11
2019-03-31$376.79K
10-Q · filed 2020-05-15
2018-12-31$211.51K
10-K · filed 2021-03-29
2017-12-31-$743.46K
10-K · filed 2020-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Genprex, Inc. (GNPX)United States$0.003B-0.02